The Role of Echocardiography in Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients

Authors Information
Article Notes and Dates
To Cite : Tadic M, Cuspidi C. The Role of Echocardiography in Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients, Int J Cancer Manag. 2017 ;10(5):e8109. doi: 10.5812/ijcm.8109.
Copyright: Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. .
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Footnotes
References
  • 1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27(9): 911-39[DOI][PubMed]
  • 2. Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011; 6(4): 189-95[DOI][PubMed]
  • 3. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978; 240(15): 1603-6[PubMed]
  • 4. Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol. 2013; 61(3): 267-74[DOI][PubMed]
  • 5. Gulati G, Zhang KW, Scherrer-Crosbie M, Ky B. Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab. Curr Heart Fail Rep. 2014; 11(4): 366-73[DOI][PubMed]
  • 6. Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009; 115(22): 5296-308[DOI][PubMed]
  • 7. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012; 104(17): 1293-305[DOI][PubMed]
  • 8. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20(5): 1215-21[DOI][PubMed]
  • 9. Tan-Chiu E, Yothers G, Romond E, Geyer CJ, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23(31): 7811-9[DOI][PubMed]
  • 10. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014; 32(20): 2159-65[DOI][PubMed]
  • 11. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J. 2009; 30(1): 98-106[DOI][PubMed]
  • 12. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013; 61(1): 77-84[DOI][PubMed]
  • 13. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010; 96(9): 701-7[DOI][PubMed]
  • 14. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011; 57(22): 2263-70[DOI][PubMed]
  • 15. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011; 130(3): 845-54[DOI][PubMed]
  • 16. Lange SA, Ebner B, Wess A, Kogel M, Gajda M, Hitschold T, et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol. 2012; 101(6): 415-26[DOI][PubMed]
  • 17. Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging. 2013; 14(3): 228-34[DOI][PubMed]
  • 18. Guerra F, Marchesini M, Contadini D, Menditto A, Morelli M, Piccolo E, et al. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Support Care Cancer. 2016; 24(7): 3139-45[DOI][PubMed]
  • 19. Fei HW, Ali MT, Tan TC, Cheng KH, Salama L, Hua L, et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography. 2016; 33(4): 519-26[DOI][PubMed]
  • 20. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab. J Am Soc Echocardiogr. 2015; 28(5): 509-14[DOI][PubMed]
  • 21. Khouri MG, Hornsby WE, Risum N, Velazquez EJ, Thomas S, Lane A, et al. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat. 2014; 143(3): 531-9[DOI]
  • 22. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. Am J Cardiol. 2011; 107(9): 1375-80[DOI]
  • 23. Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011; 12(12): 945-52[DOI][PubMed]
  • 24. Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. Eur J Cancer. 2013; 49(16): 3396-403[DOI][PubMed]
  • 25. Motoki H, Koyama J, Nakazawa H, Aizawa K, Kasai H, Izawa A, et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012; 13(1): 95-103[DOI][PubMed]
  • 26. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol. 2013; 91(8): 601-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

International Journal of Cancer Management accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check